Insider Selling: Inogen Inc. (INGN) VP Sells $372,248.00 in Stock
Inogen Inc. (NASDAQ:INGN) VP Byron Myers sold 6,200 shares of Inogen stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $60.04, for a total transaction of $372,248.00. Following the completion of the transaction, the vice president now directly owns 41,385 shares in the company, valued at approximately $2,484,755.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Byron Myers also recently made the following trade(s):
- On Friday, September 9th, Byron Myers sold 3,800 shares of Inogen stock. The shares were sold at an average price of $60.07, for a total transaction of $228,266.00.
- On Tuesday, August 9th, Byron Myers sold 13,000 shares of Inogen stock. The shares were sold at an average price of $55.00, for a total transaction of $715,000.00.
Shares of Inogen Inc. (NASDAQ:INGN) opened at 60.79 on Friday. Inogen Inc. has a 12 month low of $28.81 and a 12 month high of $61.11. The stock has a 50 day moving average of $57.82 and a 200-day moving average of $49.72. The company has a market cap of $1.22 billion, a price-to-earnings ratio of 89.40 and a beta of 0.88.
Inogen (NASDAQ:INGN) last released its earnings results on Thursday, August 4th. The medical technology company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.05. The business earned $54.57 million during the quarter, compared to the consensus estimate of $52.44 million. Inogen had a net margin of 7.86% and a return on equity of 9.50%. The company’s revenue for the quarter was up 23.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.17 EPS. On average, analysts forecast that Inogen Inc. will post $0.63 EPS for the current year.
INGN has been the topic of a number of research reports. Zacks Investment Research lowered shares of Inogen from a “buy” rating to a “hold” rating in a research note on Tuesday, August 9th. Stifel Nicolaus lowered shares of Inogen from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. They noted that the move was a valuation call. Leerink Swann reaffirmed an “outperform” rating and issued a $60.00 price target on shares of Inogen in a research note on Wednesday, June 8th. JPMorgan Chase & Co. lifted their price target on shares of Inogen from $60.00 to $62.00 and gave the company an “overweight” rating in a research note on Friday, August 5th. Finally, Needham & Company LLC reaffirmed a “strong-buy” rating and issued a $64.00 price target (up previously from $58.00) on shares of Inogen in a research note on Sunday, August 7th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $55.00.
Hedge funds have recently added to or reduced their stakes in the stock. TIAA CREF Investment Management LLC increased its stake in Inogen by 0.9% in the first quarter. TIAA CREF Investment Management LLC now owns 100,661 shares of the medical technology company’s stock worth $4,528,000 after buying an additional 940 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its stake in Inogen by 66.7% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 6,000 shares of the medical technology company’s stock worth $301,000 after buying an additional 2,400 shares in the last quarter. Bayesian Capital Management LP purchased a new stake in Inogen during the first quarter worth $238,000. Bogle Investment Management L P DE purchased a new stake in Inogen during the first quarter worth $861,000. Finally, Geode Capital Management LLC increased its stake in Inogen by 8.1% in the first quarter. Geode Capital Management LLC now owns 149,106 shares of the medical technology company’s stock worth $6,706,000 after buying an additional 11,169 shares in the last quarter.
Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or seven pounds.
Receive News & Ratings for Inogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.